Up­dat­ed: FDA pan­el backs Pfiz­er's RSV ma­ter­nal vac­cine, de­spite de­bate over safe­ty

An FDA in­de­pen­dent ad­vi­so­ry pan­el of in­fec­tious-dis­ease and vac­cine ex­perts vot­ed in gen­er­al sup­port of rec­om­mend­ing Pfiz­er’s RSV vac­cine, Abrys­vo, to pro­tect in­fants from the res­pi­ra­to­ry virus.

Af­ter lis­ten­ing to pre­sen­ta­tions from sci­en­tists from the Cen­ters for Dis­ease Con­trol and Pre­ven­tion, the FDA, and Pfiz­er, the pan­el vot­ed on two ques­tions if the da­ta sup­port the ef­fec­tive­ness and safe­ty of the vac­cine for this pop­u­la­tion. The pan­el unan­i­mous­ly vot­ed 14-0 in sup­port of ef­fi­ca­cy, and 10-4 in fa­vor of the safe­ty da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.